The GLP-1 weight-loss drug market is one of the most talked-about investment themes of the past two years. Eli Lilly (LLY) and Novo Nordisk (NVO) have become the face of this boom, turning obesity and diabetes treatments into a projected $137 billion market by 2030. The narrative is compelling: aging populations, rising obesity rates, and a seemingly insatiable demand for effective weight-loss solutions. But for investors, the key question is not whether the market is growing—it is—but whether the growth is durable, differentiated, and already reflected in valuations.

The GLP-1 Market: A Duopoly with Pricing Power

Eli Lilly and Novo Nordisk control the lion’s share of the GLP-1 market, and their dominance is not accidental. Both companies have spent decades building manufacturing capacity, distribution networks, and regulatory relationships that competitors cannot easily replicate. The recent FDA approval of Lilly’s oral GLP-1 pill in April 2026—eliminating the need for injections—further solidified its lead. This is not just a convenience upgrade; it’s a moat. Oral administration removes a major adoption barrier for patients and prescribers, expanding the addressable market beyond those willing to self-inject.

Read the full article here.